Clinicians in the dark about potential harms of commonly prescribed beta blocker
Better understanding needed to stave off overdose deaths, warns HSIB Related items fromOnMedica Withdrawn valsartan meds not linked to short-term cancer risk Too few women take part in many CVD clinical trials Pharmacists could offer high-dose statins direct to patients Cannabinoids not recommended to treat cancer-related pain GPs defend practice on prescribing statins (Source: OnMedica Latest News)
Source: OnMedica Latest News - February 19, 2020 Category: UK Health Source Type: news

Dec 6, 2019 This Week in Cardiology Dec 6, 2019 This Week in Cardiology
Vernakalent, CV death in cancer patients, dapagliflozin, and sacubitril/valsartan are the topics Dr. John Mandrola discusses in this week's podcast.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 6, 2019 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

Sun Pharma gets partial relief from US court in litigation involving three generic drugs
Drug major Sun Pharma is a defendant in a multi-district litigation brought by various classes of plaintiffs in the US District Court (District of Massachusetts), alleging a delay in the market entry for three generic drugs -- Valganciclovir, Valsartan and Esomeprazole. The company said it would continue to vigorously defend against all claims. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - December 2, 2019 Category: Pharmaceuticals Source Type: news

Making Room for New Drugs for Heart Failure Making Room for New Drugs for Heart Failure
Drs Ileana Pi ñ a and Mary Walsh discuss the latest HF updates from the American Heart Association Scientific Sessions and ask where dapagliflozin and sacubitril/valsartan will fit in the armamentarium.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 26, 2019 Category: Cardiology Tags: Cardiology Commentary Source Type: news

Valsartan Recalls Took Toll on Patients' Health
WEDNESDAY, Nov. 20, 2019 -- Emergency room visits for high blood pressure surged following last year's recall of the popular heart drug valsartan, Canadian researchers report. Within the first month of the recall, there was a 55% increase of people... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 20, 2019 Category: General Medicine Source Type: news

Recalls of Blood Pressure Med Took Toll on Patients' Health
WEDNESDAY, Nov. 20, 2019 -- Emergency room visits for high blood pressure surged following last year's recall of the popular heart drug valsartan, Canadian researchers report. Within the first month of the recall, there was a 55% increase of people... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 20, 2019 Category: General Medicine Source Type: news

AHA: Impact of Valsartan Recall Examined for Ontario, Canada
MONDAY, Nov. 18, 2019 -- The generic valsartan recall has had population-level impacts on patients in Ontario, Canada, according to a research letter published online Nov. 11 in Circulation to coincide with the annual meeting of the American Heart... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 18, 2019 Category: Pharmaceuticals Source Type: news

Sacubitril/Valsartan Benefits Extend to HF With Mildly Reduced EF Sacubitril/Valsartan Benefits Extend to HF With Mildly Reduced EF
Further analysis of the PARAGON trial also suggest the benefit of the drug combination may reach higher ejection fractions in women.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 17, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

Mylan hit with warning letter for valsartan manufacturing
The FDA sent a Mylan facility in India a warning letting for its manufacturing of APIs related to the widespread recall of blood pressure medications. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 13, 2019 Category: Pharmaceuticals Source Type: news

Generic Valsartan Abandoned After Recalls, ED Visits Rise Generic Valsartan Abandoned After Recalls, ED Visits Rise
Patients may have been willing to risk the short-term potential of uncontrolled hypertension to avoid ingesting a potential carcinogen in recalled generic valsartan medications, the authors say.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 13, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

ER visits jumped after valsartan blood pressure medication recall, study says
After issuing a recall due to an impurity called NDMA, Health Canada urged patients not to stop taking their hypertension medications without consulting their health-care providers, but some may not have listened. (Source: CBC | Health)
Source: CBC | Health - November 12, 2019 Category: Consumer Health News Tags: News/Health Source Type: news

Aurobindo Pharma under USFDA scrutiny
Aurobindo has seen intense scrutiny on the manufacturer process of valsartan, an anti-hypertension drug, that was found to contain carcinogenic impurities. Apart from Aurobindo, those impurities were detected in several other batches manufactured by drug makers. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 5, 2019 Category: Pharmaceuticals Source Type: news

valsartan, Diovan
Title: valsartan, DiovanCategory: MedicationsCreated: 3/26/1998 12:00:00 AMLast Editorial Review: 10/17/2019 12:00:00 AM (Source: MedicineNet High Blood Pressure General)
Source: MedicineNet High Blood Pressure General - October 17, 2019 Category: Cardiology Source Type: news

Exercise essential for people diagnosed with cancer
Offer cancer patients tailored exercise prescription to protect their heart from damage, even before they start chemo Related items fromOnMedica Cancer patients using complementary meds die sooner Is crowdfunding for cancer patients paying for ‘quackery’? Exercise and psychological treatments cut cancer fatigue Withdrawn valsartan meds not linked to short-term cancer risk Cigars and pipes raise mortality risk independent of cigarettes (Source: OnMedica Latest News)
Source: OnMedica Latest News - October 8, 2019 Category: UK Health Source Type: news

PROVE-HF Cracks the'Holy Grail' of Cardiac Remodeling in HFrEF PROVE-HF Cracks the'Holy Grail' of Cardiac Remodeling in HFrEF
Ileana Pi ñ a, MD speaks with lead author Jim Januzzi, MD, about the path to PROVE-HF and how sacubitril/valsartan benefits real-world patients with heart failure with reduced ejection fraction.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 7, 2019 Category: Cardiology Tags: Cardiology Commentary Source Type: news

FDA Clears Sacubitril/Valsartan for Children With Heart Failure FDA Clears Sacubitril/Valsartan for Children With Heart Failure
Sacubitril/valsartan is approved to treat symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients 1 year and older.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 3, 2019 Category: Cardiology Tags: Cardiology News Alert Source Type: news

FDA Approves Entresto (sacubitril/valsartan) for Pediatric Heart Failure
East Hanover, N.J., Oct. 1, 2019– Novartis announced today that the U.S. Food and Drug Administration (FDA) has approved Entresto (sacubitril/valsartan) for the treatment of symptomatic heart failure (HF) with systemic left ventricular... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 1, 2019 Category: Drugs & Pharmacology Source Type: news

CVS Pulls Zantac And Similar Heartburn Drugs Over Cancer Concerns
(CNN) — CVS Pharmacy has stopped selling Zantac, as well as its generic version of the heartburn medication, over concerns that they might contain a substance that could cause cancer. CVS, the largest pharmacy chain in the country, said over the weekend it was suspending sale of Zantac and other products which contain ranitidine until further notice. The US Food and Drug Administration said earlier this month that it has learned that some ranitidine — acid-reducing and heartburn medicines, including those known by the brand name Zantac — contain low levels of an impurity that could cause cancer. Zantac an...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - September 30, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Featured Health News Syndicated CBSN Boston CVS Zantac Source Type: news

Rosemarie Riddell Bogdan, Esq. Appointed to Plaintiffs ’ Steering...
Martin, Harding & Mazzotti, LLP Partner Rosemarie Riddell Bogdan appointed to a leadership position on the Plaintiffs’ Personal Injury Steering Committee in National Valsartan NDMA contamination...(PRWeb September 25, 2019)Read the full story at https://www.prweb.com/releases/rosemarie_riddell_bogdan_esq_appointed_to_plaintiffs_steering_committee_in_national_valsartan_ndma_products_liability_litigation/prweb16596119.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 25, 2019 Category: Pharmaceuticals Source Type: news

FDA Expands Recall Of Blood Pressure Drugs Again
(CNN) — Torrent Pharmaceuticals Ltd. has expanded its voluntary recall of two blood pressure medications after trace amounts of a potentially cancer-causing impurity were found during testing. The recall affects Losartan Potassium Tablets USP and Losartan Potassium/hydrochlorothiazide tablets. Tests of some of those medications revealed amounts of N-methylnitrosobutyric acid (NMBA) that were above the US Food and Drug Administration’s daily acceptable levels. This recall is related to the valsartan recall that has been expanded multiple times since July, when separate lots of blood pressure medications from dif...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - September 24, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Syndicated CBSN Boston CNN Recall Valsartan Source Type: news

Novartis Stops Distributing Generic Zantac Over Potential Cancer-Causing Ingredient
WASHINGTON (CBS) – Drug maker Novartis has halted distribution of generic versions of Zantac. The popular heartburn medication has been investigated for containing a potential cancer-causing ingredient. A Novartis spokesman told CBS News “our internal investigation is ongoing to determine further details,” and the drug can remain on pharmacy shelves for now. Sanofi, the French pharmaceutical company that makes Zantac, said it had no plans to stop distribution or production. Last week, the FDA said that ranitidine treatments like Zantac have been found to contain a “probable” carcinogenic impur...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - September 19, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Consumer Health News Syndicated CBSN Boston FDA Zantac Source Type: news

Questions raised over quality of trials supporting new cancer drugs approvals
Potential risk of bias in half of trials supporting new cancer drug approvals in Europe, study suggests Related items fromOnMedica Only half of new cancer drugs extend or improve life Drugs regulators “put profits before patients” Doctors debate long-term use of psychiatric drugs Withdrawn valsartan meds not linked to short-term cancer risk We must revise drug regulatory framework at EU and national levels (Source: OnMedica Latest News)
Source: OnMedica Latest News - September 19, 2019 Category: UK Health Source Type: news

Shock and Awe: ARNI for Acute HF May Be Safely Started in ICU Shock and Awe: ARNI for Acute HF May Be Safely Started in ICU
Some patients in cardiogenic shock may transition from IV vasoactive agents to sacubitril/valsartan without going hypotensive, suggests a small case series; PA-pressure guidance was crucial.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - September 18, 2019 Category: Intensive Care Tags: Cardiology News Source Type: news

PARAGON-HF: Is There a Role for the ARNI in HFpEF? PARAGON-HF: Is There a Role for the ARNI in HFpEF?
Ileana Pi ñ a quizzes investigator Burkert Pieske on the findings for sacubitril/valsartan in patients with HFpEF, including exploratory subgroup analyses and use of mineralocorticoid-receptor antagonists.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 16, 2019 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

Zantac Has Low Levels of a Cancer-Causing Chemical, the F.D.A. Says
The chemical, NDMA, is the same one found in the blood pressure drug valsartan, which led to widespread recalls last year. (Source: NYT)
Source: NYT - September 14, 2019 Category: American Health Authors: Katie Thomas and Sheila Kaplan Tags: Drugs (Pharmaceuticals) Heartburn Product Tests Food and Drug Administration European Medicines Agency carcinogen Zantac your-feed-healthcare Source Type: news

FDA Finds Low Levels Of Cancer-Linked Impurity In Common Heartburn Drugs
(CNN) — The US Food and Drug Administration said on Friday that it has learned that some ranitidine — acid-reducing and heartburn medicines, including those known by the brand name Zantac — contain low levels of an impurity that could cause cancer. The nitrosamine impurity known as N-nitrosodimethylamine or NDMA has been classified as a probable human carcinogen based on lab tests, and this isn’t the first time that it has been detected in a common medication. Since last year, the FDA has been investigating NDMA and other impurities in blood pressure and heart failure medicines known as angiotensin ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - September 13, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN FDA Heartburn Source Type: news

Cardiac'Shrinkage' on Sacubitril/Valsartan May Rival CRT in HF Cardiac'Shrinkage' on Sacubitril/Valsartan May Rival CRT in HF
LV volumes fell and LVEF rose, often 10 points or more, after a year on the ARNI. That approaches gains on cardiac resynchronization therapy,"the reverse-remodeling champion," a researcher notes.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 11, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

Sacubitril-Valsartan Does Not Impact Aortic Stiffness in HFrEF
WEDNESDAY, Sept. 4, 2019 -- For patients with heart failure and reduced ejection fraction (HFrEF), sacubitril-valsartan does not impact aortic stiffness versus enalapril but is associated with improvements in cardiac structure and function,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 4, 2019 Category: Pharmaceuticals Source Type: news

PARAGON-HF: Sacubitril/Valsartan Frustrates in Preserved-EF HF PARAGON-HF: Sacubitril/Valsartan Frustrates in Preserved-EF HF
Hopes were the trial would provide something new: solid clinical trial backing for an HFpEF drug therapy. It didn't, but some say it supports consideration of the drug in at least one HFpEF subgroup.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 1, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

HRT users told to discuss breast cancer risk with GP
MHRA says discussion should take place at next GP appointment after study shows persistent raised risk of breast cancer after HRT use Related items fromOnMedica Breast cancer rate falls with decline in HRT use New breast cancer drug ‘unaffordable’ for NHS NICE rejects breast cancer drug for NHS funding Withdrawn valsartan meds not linked to short-term cancer risk Data don ’t support HRT for chronic disease prevention (Source: OnMedica Latest News)
Source: OnMedica Latest News - August 30, 2019 Category: UK Health Source Type: news

valsartan/hydrochlorothiazide (Diovan HCT)
Title: valsartan/hydrochlorothiazide (Diovan HCT)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 8/19/2019 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - August 19, 2019 Category: Cardiology Source Type: news

Sacubitril/Valsartan Misses in HF, Preserved EF: PARAGON-HF Sacubitril/Valsartan Misses in HF, Preserved EF: PARAGON-HF
In the trial pitting Entresto against valsartan, the Novartis drug's effect on a composite primary end point fell short of significance in cursory top-line results announced by the company.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 30, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

American Health Packaging Issues Voluntary Nationwide Recall of Valsartan Tablets Due to the Detection of NDEA (N-Nitrosodiethylamine) Impurity
Valsartan Tablets USP (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - July 26, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Drug for hereditary ovarian cancer approved
NICE grants faster access to life-extending drug olaparib Related items fromOnMedica NICE rejects breast cancer drug for NHS funding HPV programme linked to dramatic fall in cervical disease Withdrawn valsartan meds not linked to short-term cancer risk NHS prescription charge to rise to £9 Experts disappointed at NICE decision on ovarian cancer drug (Source: OnMedica Latest News)
Source: OnMedica Latest News - July 26, 2019 Category: UK Health Source Type: news

Critical heart drug too pricey for some Medicare patients
(University of Hawaii at Manoa) An effective drug to treat chronic heart failure may cost too much for senior citizens with a standard Medicare Part D drug plan, said a study co-authored by a John A. Burns School of Medicine researcher at the University of Hawaii at Manoa. The therapy is a combination of sacubitril/valsartan called Entresto ® . Researchers found that, even with insurance, the cost to Medicare patients may be more than $1,600 a year. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 22, 2019 Category: International Medicine & Public Health Source Type: news

Popular FDA-approved heart pill found to contain deadly, cancer-causing chemical
(Natural News) An online pharmacy company known as Valisure, which is currently licensed to operate in 37 states, has issued an urgent warning to the U.S. Food and Drug Administration (FDA) about a cancer-causing chemical found in valsartan, a popular blood pressure pharmaceutical manufactured by Novartis and several other drug companies. As it turns out,... (Source: NaturalNews.com)
Source: NaturalNews.com - June 24, 2019 Category: Consumer Health News Source Type: news

Pharmacy flags another valsartan impurity, argues FDA standards are too high
Online pharmacy Valisure reported that it found a new carcinogenic impurity in some lots of blood pressure medicine valsartan, but the amount is still well below levels the FDA deemed potentially harmful. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - June 20, 2019 Category: Pharmaceuticals Source Type: news

Pharmacy Tests Turn Up Another Cancer-Causing Compound In Heart Drugs
(CNN) — Tests by an online pharmacy turned up another cancer-causing compound in heart medications, and these drugs haven’t been recalled. Drugs containing valsaratan, losartan and irbesartan made by a variety of companies in a variety of countries have been taken off pharmacy shelves since July, when tests turned up chemicals in them that are considered carcinogens. The recalls of these angiotensin II receptor blockers or ARBs continue to expand. The US Food and Drug Administration keeps a regularly updated list of the drugs that have been recalled. In this case, it’s not a recall. Instead, Valisure, an ...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - June 19, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Valsartan Source Type: news

Another cancer-causing chemical found in blood-pressure pills
Online pharmacy tells FDA it found carcinogenic solvent in valsartan heart drugs made by companies including Novartis (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - June 19, 2019 Category: Consumer Health News Source Type: news

Online pharmacy flags possible new impurity in blood pressure drug
Online pharmacy Valisure reported that it found a new cancer-causing impurity in some versions of widely prescribed blood pressure medicine valsartan, but U.S. regulators said on Tuesday that the amount in the drugs was well below levels deemed to be potentially harmful. (Source: Reuters: Health)
Source: Reuters: Health - June 18, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Antibiotic use linked to increased risk of heart attack and stroke in women
Risk is greatest for older women who take antibiotics for more than two months Related items fromOnMedica Withdrawn valsartan meds not linked to short-term cancer risk Cardio risk raised in people using long-acting bronchodilators Recurrent stroke more likely at very low BP Rising use of antithrombotics linked to subdural haematoma Adding insulin to metformin linked to higher mortality (Source: OnMedica Latest News)
Source: OnMedica Latest News - May 28, 2019 Category: UK Health Source Type: news

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Valsartan Tablets, USP, 40mg, 80mg, 160mg and 320mg Due to The Detection of Trace Amounts of N-Nitrosodimethylamine (NDMA) Impurity, Found in an Active Pharmaceutical Ingredient (API)
As a precautionary measure, Camber Pharmaceuticals, Inc. is voluntarily recalling all unexpired lots of Valsartan Tablets, USP, 40mg, 80mg, 160mg and 320mg to the hospital, retail and consumer level. This recall of multiple batches of Valsartan Tablets was prompted due to the detection of trace amounts of N-Nitrosodimethylamine (NDMA), a possible process impurity or contaminant in an active pharmaceutical ingredient, manufactured by Hetero Labs Limited, Unit – I (API manufacturer). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 24, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Valsartan / Amlodipine / HCTZ Tablets
Torrent Pharmaceuticals Limited is voluntarily recalling 14 lots of Valsartan/Amlodipine/HCTZ tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceuticals. The impurity detected in the API is N-nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification. (Source: FDA Center for Drug...
Source: FDA Center for Drug Evaluation and Research - What's New - May 24, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Prinston Pharmaceutical Inc Issues Voluntary Nationwide Recall of Valsartan and Valsartan HCTZ Tablets Due to Detection of a Trace Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA) in The Products
Prinston Pharmaceutical Inc. dba Solco Healthcare LLC. is recalling all lots of Valsartan Tablets, 40 mg, 80mg, 160mg, and 320mg; and Valsartan-Hydrochlorothiazide Tablets, 80mg/12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg, and 320mg/25mg to the retail level. This product recall is due to the detection of a trace amount of an unexpected impurity, N-nitrosodimethylamine (NDMA), made by the manufacturer – Zhejiang Huahai Pharmaceutical Co. Ltd. -- that is used in the manufacture of the subject product lots. This impurity has been classified as a probable human carcinogen as per International Agency for Research on Ca...
Source: FDA Center for Drug Evaluation and Research - What's New - May 23, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Mylan Expands Its Voluntary Nationwide Recall of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, to all Lots Within Expiry Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceuti
Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is expanding its consumer-level voluntary nationwide recall to include all lots of Valsartan-containing products within expiry. The 104 additional lots include 26 lots of Amlodipine and Valsartan Tablets, USP (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 22, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

AurobindoPharma USA, Inc. Initiates a Voluntary Nationwide Consumer Level Recall Expansion of 38 Lots of Amlodipine Valsartan Tablets USP and Valsartan Tablets, USP due to the detection of NDEA (N-Nitrosodiethylamine) Impurity.
AurobindoPharma USA, Inc. is conducting a voluntary recall expansion of 38 lots of Valsartan and Amlodipine and Valsartan tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in the finished drug producAurobindoPharma USA, Inc. is conducting a voluntary (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - May 21, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

How Some Generic Drugs Could Do More Harm Than Good
For the 16 years that Dr. Brian Westerberg, a Canadian surgeon, worked volunteer missions at the Mulago National Referral Hospital in Kampala, Uganda, scarcity was the norm. The patients usually exceeded the 1,500 allotted beds. Running water was once cut off when the debt-ridden hospital was unable to pay its bills. On some of his early trips, Westerberg even brought over drugs from Canada in order to treat patients. But as low-cost generics made in India and China became widely available through Uganda’s government and international aid agencies in the early 2000s, it seemed at first like the supply issue had been ...
Source: TIME: Health - May 17, 2019 Category: Consumer Health News Authors: Katherine Eban Tags: Uncategorized generic drugs medication medicine Source Type: news

Swarms of bugs, missing data plague firms now making heart drug
Last month, the FDA posted a list of 43 versions of valsartan and similar drugs that don ’t contain carcinogens. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 16, 2019 Category: Pharmaceuticals Source Type: news

More Losartan Joins Recall List, Heritage Pharma Distributors More Losartan Joins Recall List, Heritage Pharma Distributors
Manufacturer Vivimed has recalled 19 lots of its losartan potassium found with the same potential carcinogen that has led to recalls of both losartan and valsartan from various companies.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 6, 2019 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news

Exforge (Amlodipine and Valsartan) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 3, 2019 Category: Drugs & Pharmacology Source Type: news